Liminatus Pharma, Inc. Class A Common Stock (LIMN) Earnings Analysis
Liminatus Pharma, Inc. Class A Common Stock (LIMN) has no confirmed upcoming earnings date. Trailing P/E -0.30.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does LIMN next report earnings?
No confirmed upcoming earnings date is currently scheduled for LIMN. This page updates as the calendar is published.
LIMN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-15 | -0.03 USD | n/a | n/a | n/a |
| 2026-03-31 | -0.03 USD | n/a | n/a | n/a |
| 2025-11-13 | -0.07 USD | n/a | n/a | n/a |
| 2025-10-03 | -0.05 USD | n/a | n/a | n/a |
LIMN valuation and analyst view
| Trailing P/E | -0.30 |
|---|---|
| Trailing EPS | -0.4632 USD |
| Price / book | -21.86 |
| Dividend yield | 0.00% |
| Market cap | 0.00B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Liminatus Pharma, Inc. Class A Common Stock (LIMN)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for LIMN. This page updates as the calendar is published.
Did LIMN beat earnings last quarter?
Consensus estimate data was not available for LIMN's 2026-05-15 report.
What is LIMN's current P/E ratio and EPS?
LIMN trades at a trailing P/E of -0.30 on trailing EPS of -0.46320233837781205 USD.
What do analysts rate LIMN?
LIMN has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.